Last reviewed · How we verify
Antiretroviral treatment
Antiretroviral treatment, marketed by Makerere University, holds a position in the HIV treatment landscape with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Antiretroviral treatment |
|---|---|
| Also known as | Assessment of non communicable diseases and geriatric syndromes |
| Sponsor | Makerere University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
- Opioid, HIV and Immune System (PHASE4)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
- Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption (PHASE2)
- Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiretroviral treatment CI brief — competitive landscape report
- Antiretroviral treatment updates RSS · CI watch RSS
- Makerere University portfolio CI